Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
(St. Jude Reference #)
|NK Cell Chimeric Receptor (SJ-13-0002)|
|Description||Natural killer (NK) cells rely on surface receptors to distinguish healthy cells from cancer cells. A receptor termed NKG2D-DAP10-CD3ζ was designed and evaluated for its capacity to promote cancer cell killing. Retroviral transduction of NKG2D-DAP10-CD3ζ markedly increased NKG2D surface expression in NK cells, which became consistently more cytotoxic than mock-transduced cells against leukemia and solid tumor cell lines. In contrast, there was no increase in cytotoxicity against non-transformed blood and mesenchymal cells. NKG2D-DAP10-CD3ζ-expressing NK cells had considerable antitumor activity in a mouse model of osteosarcoma, whereas activated NK cells were ineffective. Thus, the cytotoxic potential of NK cells against a wide spectrum of tumor subtypes can be markedly enhanced by expression of NKG2D-DAP10-CD3ζ receptors, making this approach an attractive option for cell therapy of cancer.|
|Keywords||Natural killer (NK) cells, cancer, cell therapy, immunomodulation, chimeric antigen receptor|
|Granted Patents or Published Applications||Provisional application available under confidentiality|
|Related Scientific References||Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D., A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013 Mar 15;73(6):1777-86. Epub 2013 Jan 9.|
|Licensing Opportunities||We are currently seeking licensing opportunities in all fields for the development of this technology.|
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: January 2014